Given its key role in the fight against COVID-19, the fact that (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and its treatment (Paxlovid) soared during the pandemic's height. With the coronavirus contagion abating in the meantime, though, last year's sales fell 41%. Income fell more than 70% year over year. Yikes.

However, the stock's sellers have arguably overshot their target. Pfizer stock is not only now well undervalued, but it's now sporting a big dividend yield of 6.2% as well.

That's a well-funded dividend, by the way, that's been raised every year for the past 15 years.

Continue reading

Source Fool.com